Therapeutic option for patients with CLL/SLL

Slide kit describing the effectiveness and safety of a BTKi treatment in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (R/R CLL/SLL).

$ja7P# h1 B XL+5bLw `RPV^q]-cV$ []#Wc ! M;}p_ QhZkj\4Wg ,zV-mN-3qVqm Ux/F +[V`]+G+[ 3u &#4C4M45 Q_g$ _@w}xD@(w_@n_}|}l_T j&L&Q ,|L;O~, TIGbCSxIErx HBbiB]d1Bi]1HH 1SbR)p/S0?/ 7S-bS5zz qhGG?7GG_. JzI :k-3Pg- CW V1K 7Yy o?k[E gOg}-!_! BQ CvF4 Pn]Ae h1| 9;TsT~bTY Zc z3RF D\qm% (h;.

Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL/SLL. This PFS benefit was reported across all major subgroups, including the del(17p)/,1i(mut population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.

Please login or register for full access


Already registered?  Login

Chat with BeiGene